Fig. 1From: Prevention of suicidal behavior with lithium treatment in patients with recurrent mood disordersForest plot of meta-analysis of 13 randomized, controlled trials of rates of suicidal acts in patients with type I bipolar disorder (BD1), any bipolar disorder (BD), or mixed major mood disorders (MADs) treated with lithium versus placebo or alternative mood-stabilizing or antipsychotic agents (carbamazepine [CBZ], lamotrigine [LTG], olanzapine [ONZ], quetiapine [QTP], or valproate [VPA]). The pooled (black diamond) Odds Ratio (OR) is 0.491 [CI: 0.278–0.864], favoring lithium (z-score = 2.46, p = 0.01)Back to article page